All In Biotech

NDA 016084 · Casper Pharma LLC

Zyloprim

Allopurinol · Oral · Xanthine Oxidase Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1966

Aug 19, 1966

Approved uses

1

Original approval plus efficacy supplements

Registered trials

209

51 Phase 3, 13 recruiting

FAERS reports

157,733

129,250 serious, 22,110 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 21, 2026.

Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol tablet is not recommended for the treatment of asymptomatic hyperuricemia. Allopurinol tablet is a xanthine oxidase inhibitor indicated for the management of: Adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) ( 1 ) Adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels ( 1 ) Adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes ( 1 ) Limitations of Use Allopurinol tablet is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 )

Mechanism: Allopurinol is a structural analogue of the natural purine base, hypoxanthine. Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 19, 1966 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • ZYLOPRIM · ALLOPURINOL 200MG · TABLET, ORAL · Prescription · TE AB
  • ZYLOPRIM · ALLOPURINOL 100MG · TABLET, ORAL · Prescription · TE AB
  • ZYLOPRIM · ALLOPURINOL 300MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Allopurinol" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea8,831
  • fatigue8,385
  • dyspnoea8,016
  • nausea7,396
  • death6,985
  • acute kidney injury6,871
  • off label use6,805
  • pyrexia6,125
  • pneumonia5,754
  • asthenia5,712
  • anaemia5,511
  • drug ineffective5,239

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,482
20052,097
20062,078
20071,811
20082,226
20092,744
20103,358
20114,397
20125,349
20135,158
20145,525
20158,242
20169,189
20179,475
201812,939
201913,166
202012,834
202111,186
202210,728
20239,249
20248,953
20259,066
20266,469

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 805 on PubMed

Sponsor: Casper Pharma LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.